C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
The clinical impact of c-erbB-3 has seldom been assessed in patients with non small cell lung cancer (NSCLC). Forty-three NSCLC patients treated by erlotinib for c-erbB-3 and EGFR expression were investigated by immunohistochemistry analysis. Two partial responses, one minor response, two stable diseases and twenty progressive diseases were observed at the first evaluation. Seventeen patients died before evaluation. Median EGFR expression was 70% of the cancer cells. Forty-two percent of the tumours co-expressed c-erbB-3 and EGFR without any difference according to histology or disease stage. There was no correlation between c-erbB-3 and EGFR expression. Median survival time was 2.6 months and the six months survival rate was 21%. There was no detectable impact of EGFR (p=0.94) or c-erbB-3 (p=0.93) expression on survival. In this small particular cohort of NSCLC patients receiving salvage therapy with erlotinib, there was no correlation between c-erbB-3 expression and clinical parameters, nor between cerbB-3/EGFR expression and outcome.